

## Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following drug types best reflects the mechanism of action of rilvegostomig?
  - Monoclonal antibody targeting TIGIT
  - Bispecific antibody targeting PD-1 and TIGIT
  - Antibody-drug conjugate targeting TIGIT
- The Phase III ARTEMIDE-Biliary01 study is evaluating rilvegostomig in combination with chemotherapy for patients with biliary tract cancer in which of the following settings?
  - As first-line therapy for metastatic disease
  - As second-line therapy for metastatic disease after disease progression on first-line chemoimmunotherapy
  - As adjuvant therapy
  - As neoadjuvant therapy for patients with borderline-resectable disease
- Which of the following statements is true regarding patients enrolled in the Phase III DESTINY-Gastric04 study evaluating trastuzumab deruxtecan versus ramucirumab/paclitaxel in the second-line setting for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma?
  - HER2 status was based on archival tissue
  - A biopsy to reaffirm the patient's HER2 status after disease progression on a first-line trastuzumab-containing regimen was mandatory
  - Participants could have any degree of HER2 positivity on IHC (3+, 2+ or 1+)
  - I'm not sure
- What is the approximate median duration of response observed with zanidatamab in the HERIZON-BTC-01 study evaluating therapy for HER2-amplified unresectable locally advanced or metastatic biliary tract cancer?
  - 7 months
  - 15 months
  - 29 months